← Back to Search


HDR Brachytherapy for Prostate Cancer

Waitlist Available
Led By Hans Chung, MD
Research Sponsored by Sunnybrook Health Sciences Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Staging CT or MRI (abdomen and pelvis) and bone scan negative for metastases
ECOG performance status 0-1
Must not have
Evidence of castrate resistance (defined as PSA > 3 ng/mL while testosterone is < 1.7 nmol/L)
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights


This trial is looking at the feasibility and toxicities of treating localized prostate cancer with radioactive seeds, in the hopes that this will be a less invasive option with fewer complications than other treatment options.

Who is the study for?
Men with isolated local recurrence of prostate cancer after initial radiation therapy, who have a solitary recurrence confirmed by MRI and biopsy, PSA levels below 10 ng/mL, prostate volume under 50cc, good performance status (ECOG 0-1), no metastases on CT/MRI or bone scan, manageable urinary symptoms (IPSS < 15), and no prior extensive prostate treatments like TURP or chemotherapy.Check my eligibility
What is being tested?
The trial is testing focal salvage HDR brachytherapy—a targeted internal radiation treatment where radioactive seeds are temporarily implanted in the prostate. This pilot study aims to assess how feasible this approach is and what side effects it might cause when treating only the affected part of the prostate.See study design
What are the potential side effects?
Potential side effects may include urinary issues due to irritation from the radioactive seeds, bowel problems if nearby tissues are affected by radiation, sexual dysfunction as a result of nerve damage near the treated area, and general discomfort associated with invasive procedures.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
My scans show no cancer spread to my abdomen, pelvis, or bones.
I am fully active or can carry out light work.
My prostate is smaller than 50cc.
My MRI shows a single cancer recurrence in my prostate.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
My prostate cancer is resistant to hormone therapy.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of acute urinary and rectal toxicities
Secondary outcome measures
Acute and late urinary toxicities
Biochemical (ie. prostate specific antigen) disease free survival
Incidence of late urinary and rectal toxicities
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Focal salvage HDR prostate brachytherapyExperimental Treatment1 Intervention

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Localized radiation therapy, such as the temporary implantation of radioactive seeds (brachytherapy), works by placing radioactive material directly into the prostate. These seeds emit radiation over time, targeting and killing cancer cells while sparing surrounding healthy tissue. This precision reduces side effects compared to external beam radiation. For prostate cancer patients, this means an effective treatment option with potentially fewer complications and a focus on preserving quality of life.
Prostate Leiomyosarcoma: A Rare Misleading Tumor.Hormonal therapy in the management of prostate cancer: from Huggins to the present.

Find a Location

Who is running the clinical trial?

Sunnybrook Health Sciences CentreLead Sponsor
661 Previous Clinical Trials
1,553,991 Total Patients Enrolled
34 Trials studying Prostate Cancer
12,578 Patients Enrolled for Prostate Cancer
Canadian Association of Radiation OncologyIndustry Sponsor
7 Previous Clinical Trials
442 Total Patients Enrolled
4 Trials studying Prostate Cancer
192 Patients Enrolled for Prostate Cancer
Hans Chung, MDPrincipal InvestigatorSunnybrook Health Sciences Centre, Odette Cancer Centre
1 Previous Clinical Trials
30 Total Patients Enrolled

Media Library

Focal Salvage HDR Brachytherapy (Brachytherapy) Clinical Trial Eligibility Overview. Trial Name: NCT01583920 — N/A
Prostate Cancer Research Study Groups: Focal salvage HDR prostate brachytherapy
Prostate Cancer Clinical Trial 2023: Focal Salvage HDR Brachytherapy Highlights & Side Effects. Trial Name: NCT01583920 — N/A
Focal Salvage HDR Brachytherapy (Brachytherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01583920 — N/A
~15 spots leftby Jul 2028